‍

Daewoong Pet, a company specializing in pet healthcare, has launched AlphaNex, a complex probiotic product designed exclusively for veterinary hospitals. AlphaNex is the follow-up product to the pancreatic enzyme supplement Epicle, which was released in July of the previous year.

AlphaNex combines probiotics and three types of enzymes (amylase, protease, and lipase) to break down carbohydrates, fats, and proteins. It also includes indigestible maltodextrin and fructooligosaccharides, which serve as food sources for the probiotics.

The product uses a fiber coating patented technology to protect the probiotics in the acidic environment of the stomach, enhancing their survival rate. This patented formulation from Daewoong Therapeutics neutralizes stomach acid, preventing the probiotics from being destroyed by gastric juices.

In line with Daewoong Pet's development principle of "Human Standard", AlphaNex is produced using:

Ingredients that are safe for human consumption,

Collaboration with facilities that manufacture health food for humans,

Food-grade quality control standards,

Compliance with nutritional labeling standards for ingredient content.

Lee Hyo-jun, CEO of Daewoong Pet, stated, “AlphaNex is a customized, complex probiotic product that takes into consideration the fact that pets cannot easily take probiotics on an empty stomach like humans. Along with Epicle and AlphaNex, we will continue to expand our lineup of digestive enzyme supplements that are effective in improving digestive disorders, striving to improve the quality of life for elderly pets.”